참고문헌
- Fujita K, Hosomi M, Nakagawa M, et al (2014). White blood cell count is positively associated with benign prostatic hyperplasia. Int J Urol, 21, 308-2. https://doi.org/10.1111/iju.12243
- Fujita K, Imamura R, Tanigawa G, et al (2012). Low serum neutrophil count predicts a positive prostate biopsy. Prostate Cancer Prostatic Dis, 15, 386-0. https://doi.org/10.1038/pcan.2012.27
- Gorelick C, Andikyan V, Mack M, Lee YC, Abulafia (2009). Prognostic significance of preoperative thrombocytosis in patients with endometrial carcinoma in an innercity population. Int J Gynecol Cancer, 19, 1384-9. https://doi.org/10.1111/IGC.0b013e3181a47d47
- Gueron G, De Siervi A, Vazquez E (2012). Advanced prostate cancer: reinforcing the strings between inflammation and the metastatic behavior. Prostate Cancer Prostatic Dis, 15, 213-1 https://doi.org/10.1038/pcan.2011.64
- Gungor T, Kanat-Pektas M, Sucak A, Mollamahmutoglu L (2009). The role of thrombocytosis in prognostic evaluation of epithelial ovarian tumors. Arch Gynecol Obstet, 279, 53-6. https://doi.org/10.1007/s00404-008-0673-9
- Jarnicki A, Putoczki T, Ernst M (2010). Stat3: linking inflammation to epithelial cancer more than a "gut" feeling? Cell Div, 5, 14. https://doi.org/10.1186/1747-1028-5-14
- Kantoff PW, Higano CS, Shore ND, et al (2010). Sipuleucel-T immunotherapy for castration-resistant prostate cancer. N Engl J Med, 363, 411-2. https://doi.org/10.1056/NEJMoa1001294
- Karazanashvili G (2008). Editorial comment on: the relationship between prostate inflammation and lower urinary tract symptoms: examination of baseline data from the REDUCE trial. Eur Urol, 54, 1383-4. https://doi.org/10.1016/j.eururo.2007.11.027
- Keizman D, Gottfried M, Ish-Shalom M, et al (2012). Pretreatment neutrophil-to-lymphocyte ratio in metastatic castration-resistantprostate cancer patients treated with ketoconazole: association with outcome and predictive nomogram. Oncologist, 17, 1508-4. https://doi.org/10.1634/theoncologist.2012-0125
- Kerpsack JT, Finan MA (2000). Thrombocytosis as a predictor of malignancy in women with a pelvic mass. J Reprod Med, 45, 929-2.
- Kramer G, Mitteregger D, Marberger M (2007). Is benign prostatic hyperplasia (BPH) an immune inflammatory disease? Eur Urol, 51, 1202-6. https://doi.org/10.1016/j.eururo.2006.12.011
- Li AJ, Madden AC, Cass I, et al (2004). The prognostic significance of thrombocytosis in epithelial ovarian carcinoma. Gynecol Oncol, 92, 211-4. https://doi.org/10.1016/j.ygyno.2003.09.002
- Mantovani A, Allavena P, Sica A, Balkwill F (2008). Cancerrelated inflammation. Nature, 454, 436-4. https://doi.org/10.1038/nature07205
- McDonald AC, Vira MA, Vidal AC, et al (2014). Association between systemic inflammatory markers and serum prostatespecific antigen in men without prostatic disease - the 2001-2008 national health and nutrition examination survey. Prostate, 74, 561-7. https://doi.org/10.1002/pros.22782
- Mengus C, Le Magnen C, Trella E, et al (2011). Elevated levels of circulating IL-7 and IL-15 in patients with early stage prostate cancer. J Transl Med, 9, 162. https://doi.org/10.1186/1479-5876-9-162
- Mistry K, Cable G (2003). Meta-analysis of prostatespecific antigen and digital rectal examination as screening tests for prostate carcinoma. J Am Board Fam Pract, 16, 95-1. https://doi.org/10.3122/jabfm.16.2.95
- Nuhn P, Vaghasia AM, Goyal J, et al (2013). Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castrationresistantprostate cancer (mCRPC) treated with first-line docetaxel. BJU Int, e-pub ahead of print, doi: 10.1111/bju.12531.
- Palapattu GS, Sutcliffe S, Bastian PJ, et al (2005). Prostate carcinogenesis and inflammation: emerging insights. Carcinogenesis, 26, 1170-1.
- Pond GR, Armstrong AJ, Wood BA, et al (2012). Ability of C-reactive protein to complement multiple prognostic classifiers in men with metastatic castration resistant prostate cancer receiving docetaxel-based chemotherapy. BJU Int, 110, 461-8. https://doi.org/10.1111/j.1464-410X.2012.11148.x
- Prins RC, Rademacher BL, Mongoue-Tchokote S, et al (2012). C-reactive protein as an adverse prognostic marker for men with castration-resistant prostate cancer (CRPC): confirmatory results. Urol Oncol, 30, 33-7. https://doi.org/10.1016/j.urolonc.2009.11.012
- Roehl KA, Antenor JA, Catalona WJ (2002). Serial biopsy results in prostate cancer screening study. J Urol, 167, 2435-9. https://doi.org/10.1016/S0022-5347(05)64999-3
- Schaider H, Oka M, Bogenrieder T, et al (2003). Differential response of primary and metastatic melanomas to neutrophils attracted by IL-8. Int J Cancer, 103, 335-3. https://doi.org/10.1002/ijc.10775
- Shafique K, Proctor MJ, McMillan DC, et al (2012). Systemic inflammation and survival of patients with prostate cancer: evidence from the glasgow inflammation outcome study. Prostate Cancer Prostatic Dis, 15, 195-1. https://doi.org/10.1038/pcan.2011.60
- Shafique K, Proctor MJ, McMillan DC, et al (2013). The modified glasgow prognostic score in prostate cancer: results from a retrospective clinical series of 744 patients. BMC Cancer, 13, 292. https://doi.org/10.1186/1471-2407-13-292
- Sonpavde G, Pond GR, Armstrong AJ, et al (2014). Prognostic impact of the neutrophil-to-lymphocyte ratio in men with metastatic castration-resistant prostate cancer. Clin Genitourin Cancer, 12, 317-4. https://doi.org/10.1016/j.clgc.2014.03.005
- Sumbul AT, Sezer A, Abali H, et al (2014). Neutrophil-tolymphocyte ratio predicts PSA response, but notoutcomes in patients with castration-resistant prostate cancer treated withdocetaxel. Int Urol Nephrol, 46, 1531-5. https://doi.org/10.1007/s11255-014-0664-7
- Tai CG, Johnson TV, Abbasi A, et al (2014). External validation of the modified glasgow prognostic score for renal cancer. Indian J Urol, 30, 33-7. https://doi.org/10.4103/0970-1591.124203
- Tanik S, Albayrak S, Zengin K, et al (2014). Is the neutrophillymphocyte ratio an indicator of progression in patients with benign prostatic hyperplasia? Asian Pac J Cancer Prev, 15, 6375-9. https://doi.org/10.7314/APJCP.2014.15.15.6375
- Templeton AJ, Pezaro C, Omlin A, et al (2014). Simple prognostic score for metastatic castration-resistant prostate cancer with incorporation of neutrophil-to-lymphocyte ratio. Cancer, 120, 3346-2. https://doi.org/10.1002/cncr.28890
피인용 문헌
- Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy vol.16, pp.1, 2016, https://doi.org/10.1186/s12885-016-2363-5
- Predictive value of neutrophil-to-lymphocyte ratio in diagnosis of prostate cancer among men who underwent template-guided prostate biopsy vol.95, pp.44, 2016, https://doi.org/10.1097/MD.0000000000005307
- Clinical implications of pretreatment inflammatory biomarkers as independent prognostic indicators in prostate cancer pp.08878013, 2017, https://doi.org/10.1002/jcla.22277
- A Case of Prostatic Carcinoma Manifesting as Cutaneous Facial Nodule vol.2018, pp.2090-6978, 2018, https://doi.org/10.1155/2018/5265909
- Platelet-lymphocyte ratio (PLR) and all-cause mortality in general population: insights from national health and nutrition education survey pp.1369-1635, 2019, https://doi.org/10.1080/09537104.2019.1571188